United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC reduced its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,583 shares of the biotechnology company’s stock after selling 464 shares during the period. Mutual of America Capital Management LLC owned approximately 0.05% of United Therapeutics worth $8,321,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics in the 4th quarter valued at $25,000. Brooklyn Investment Group acquired a new stake in United Therapeutics during the 3rd quarter worth about $33,000. Capital Performance Advisors LLP purchased a new stake in shares of United Therapeutics during the 3rd quarter worth about $82,000. MassMutual Private Wealth & Trust FSB raised its stake in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after purchasing an additional 58 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in shares of United Therapeutics during the 3rd quarter worth about $111,000. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Down 1.1 %

Shares of NASDAQ UTHR opened at $319.96 on Monday. United Therapeutics Co. has a 12 month low of $221.53 and a 12 month high of $417.82. The company has a market cap of $14.28 billion, a P/E ratio of 14.05, a P/E/G ratio of 0.97 and a beta of 0.57. The business’s 50 day moving average is $359.65 and its two-hundred day moving average is $360.97.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same quarter last year, the firm earned $4.36 EPS. Sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Thursday. Finally, UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $388.25.

Insider Transactions at United Therapeutics

In related news, Director Nilda Mesa sold 255 shares of the business’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the sale, the director now owns 5,528 shares of the company’s stock, valued at $1,966,696.56. The trade was a 4.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total value of $2,882,649.00. Following the completion of the sale, the executive vice president now directly owns 36,710 shares in the company, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 124,164 shares of company stock valued at $45,278,893. 11.90% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.